Brought to you by 
Teva divests generics portfolio to Mayne for $652mm
11 May 2022
Executive Summary
Mayne Pharma Group Ltd acquired a portfolio of 37 approved generics and 5 generics pending FDA approval from Teva Pharmaceutical Industries Ltd. for $652mm in cash.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
-
Drug Delivery
- Controlled Release
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Product Purchase
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Teva divests generics portfolio to Mayne for $652mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice